BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Favaloro EJ, Henry BM, Lippi G. COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check? Semin Thromb Hemost 2021. [PMID: 34130340 DOI: 10.1055/s-0041-1728832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Nwagha TU, Nweke M, Ezigbo ED. Contributions of von Willebrand factor to clinical severity of sickle cell disease: a systematic review and metanalysis. Hematology 2022;27:860-6. [PMID: 35938970 DOI: 10.1080/16078454.2022.2107908] [Reference Citation Analysis]
2 Barreira GA, Santos EHD, Pereira MFB, Rodrigues KA, Rocha MC, Kanunfre KA, Marques HHS, Okay TS; Pediatric COVID-19 HC-FMUSP Study Group. Technical performance of a lateral flow immunoassay for detection of anti-SARS-CoV-2 IgG in the outpatient follow-up of non-severe cases and at different times after vaccination: comparison with enzyme and chemiluminescent immunoassays. Rev Inst Med Trop Sao Paulo 2022;64:e49. [PMID: 35858039 DOI: 10.1590/S1678-9946202264049] [Reference Citation Analysis]
3 Espinosa G, Zamora-martínez C, Pérez-isidro A, Neto D, Bravo-gallego LY, Prieto-gonzález S, Viñas O, Moreno-castaño AB, Ruiz-ortiz E, Cervera R; The COVAPS-CLINIC Study Group Investigators. Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. Front Immunol 2022;13:911979. [DOI: 10.3389/fimmu.2022.911979] [Reference Citation Analysis]
4 Rizk JG, Gupta A, Lazo JG Jr, Sardar P, Henry BM, Lavie CJ, Effron MB. To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Semin Thromb Hemost 2022. [PMID: 35468641 DOI: 10.1055/s-0042-1744302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
5 Achim A, Kákonyi K, Jambrik Z, Ruzsa Z. A case report of COVID-19-associated acute hand ischaemia in a young professional volleyball player. Eur Heart J Case Rep 2022;6:ytac099. [PMID: 35345423 DOI: 10.1093/ehjcr/ytac099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lippi G, Henry BM, Favaloro EJ. The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties. Semin Thromb Hemost 2022. [PMID: 35158389 DOI: 10.1055/s-0042-1742740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Lippi G, Favaloro EJ. What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19. Semin Thromb Hemost 2022. [PMID: 35021250 DOI: 10.1055/s-0041-1742091] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bahraini M, Dorgalaleh A. The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Semin Thromb Hemost 2021. [PMID: 34695858 DOI: 10.1055/s-0041-1736166] [Reference Citation Analysis]
9 Stelzer M, Henes J, Saur S. The Role of Antiphospholipid Antibodies in COVID-19. Curr Rheumatol Rep 2021;23:72. [PMID: 34259944 DOI: 10.1007/s11926-021-01041-7] [Reference Citation Analysis]